Trinity Biotech PLC (NASDAQ:TRIB) Short Interest Down 39.6% in June

Posted by on Jul 1st, 2026

Trinity Biotech PLC (NASDAQ:TRIB – Get Free Report) saw a large drop in short interest in June. As of June 15th, there was short interest totaling 144,829 shares, a drop of 39.6% from the May 31st total of 239,691 shares. Approximately 4.4% of the company’s stock are short sold. Based on an average trading volume of 145,980 shares, the days-to-cover ratio is currently 1.0 days.

Trinity Biotech Trading Down 13.6%

Shares of NASDAQ:TRIB traded down $0.05 during trading on Wednesday, hitting $0.34. 619,055 shares of the company were exchanged, compared to its average volume of 760,692. Trinity Biotech has a fifty-two week low of $0.31 and a fifty-two week high of $3.44. The stock has a market cap of $1.21 million and a price-to-earnings ratio of -0.19. The firm has a fifty day moving average price of $0.60 and a two-hundred day moving average price of $0.71.

Trinity Biotech (NASDAQ:TRIB – Get Free Report) last released its quarterly earnings data on Tuesday, June 16th. The company reported ($0.23) EPS for the quarter, beating the consensus estimate of ($0.31) by $0.08. The company had revenue of $10.85 million during the quarter, compared to analyst estimates of $10.68 million.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of TRIB. Perceptive Advisors LLC bought a new stake in shares of Trinity Biotech in the 2nd quarter valued at about $1,164,000. Citadel Advisors LLC grew its holdings in Trinity Biotech by 196.1% during the third quarter. Citadel Advisors LLC now owns 39,384 shares of the company’s stock worth $41,000 after purchasing an additional 26,084 shares during the period. Hunter Associates Investment Management LLC increased its position in Trinity Biotech by 8.1% during the fourth quarter. Hunter Associates Investment Management LLC now owns 526,610 shares of the company’s stock worth $417,000 after buying an additional 39,500 shares during the last quarter. Williams & Novak LLC increased its position in Trinity Biotech by 677.5% during the fourth quarter. Williams & Novak LLC now owns 93,300 shares of the company’s stock worth $74,000 after buying an additional 81,300 shares during the last quarter. Finally, Yorkville Advisors Global LP bought a new stake in Trinity Biotech in the first quarter valued at approximately $122,000. 78.97% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings cut shares of Trinity Biotech from a “sell (d-)” rating to a “sell (e+)” rating in a report on Friday, May 8th. One research analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, Trinity Biotech has a consensus rating of “Reduce”.

Get Our Latest Stock Report on TRIB

Trinity Biotech Company Profile

(Get Free Report)

Trinity Biotech plc is a global diagnostic healthcare company headquartered in Bray, Ireland. The firm specializes in the development, manufacture and marketing of in vitro diagnostic products aimed at the detection and management of chronic and infectious diseases. Its offerings are designed to deliver timely and accurate results for a range of healthcare settings, from central laboratories to point‐of‐care environments.

The company’s product portfolio includes a comprehensive array of assays and instrumentation.

Featured Articles

Receive News & Ratings for Trinity Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trinity Biotech and related companies with MarketBeat.com's FREE daily email newsletter.